These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16455452)

  • 1. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.
    Li J; Zhu J; Melvin WS; Bekaii-Saab TS; Chen CS; Muscarella P
    J Gastrointest Surg; 2006 Feb; 10(2):207-14. PubMed ID: 16455452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
    Zhu J; Huang JW; Tseng PH; Yang YT; Fowble J; Shiau CW; Shaw YJ; Kulp SK; Chen CS
    Cancer Res; 2004 Jun; 64(12):4309-18. PubMed ID: 15205346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
    Jiang C; Yi XP; Shen H; Li YX
    World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
    Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
    Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
    Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
    Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
    Yao J; Qian C
    Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
    Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
    Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
    Ng SSW ; Tsao MS; Chow S; Hedley DW
    Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
    Fryer RA; Barlett B; Galustian C; Dalgleish AG
    Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.
    Bharadwaj U; Marin-Muller C; Li M; Chen C; Yao Q
    Mol Cancer; 2011 Aug; 10():106. PubMed ID: 21880146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid.
    Balasubramanian S; Chandraratna RA; Eckert RL
    Carcinogenesis; 2004 Aug; 25(8):1377-85. PubMed ID: 14976133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway.
    Wu Y; Xu W; Yang Y; Zhang Z
    Ann Clin Lab Sci; 2021 May; 51(3):310-320. PubMed ID: 34162560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Clin Cancer Res; 2001 Oct; 7(10):3269-75. PubMed ID: 11595724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.
    Huanwen W; Zhiyong L; Xiaohua S; Xinyu R; Kai W; Tonghua L
    Mol Cancer; 2009 Dec; 8():125. PubMed ID: 20021699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
    Amrutkar M; Aasrum M; Verbeke CS; Gladhaug IP
    BMC Cancer; 2019 Jun; 19(1):596. PubMed ID: 31208372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
    El-Rayes BF; Ali S; Sarkar FH; Philip PA
    Mol Cancer Ther; 2004 Nov; 3(11):1421-6. PubMed ID: 15542781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
    Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
    Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.